<DOC>
	<DOCNO>NCT01590342</DOCNO>
	<brief_summary>The primary objective demonstrate clinical benefit diclofenac ( added standard anticoagulant therapy ) placebo normotensive patient acute symptomatic pulmonary embolism right ventricular dysfunction . The secondary objective ass safety administration diclofenac normotensive patient acute symptomatic pulmonary embolism right ventricular dysfunction .</brief_summary>
	<brief_title>Diclofenac Submassive PE</brief_title>
	<detailed_description />
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>1 . Acute symptomatic PE confirm multidetector CT angiography , highprobability V/Q scan , presence deep vein thrombosis confirm low limb ultrasound test patient nonconclusive V/Q scan ; 2. first symptom occur ten day le randomization ; 3. haemodynamic stability ( systolic blood pressure &gt; 100 mm Hg , need inotropic support , pulmonary resuscitation , intubation thrombolytic treatment ) ; 4. right ventricular dysfunction assess transthoracic echocardiography within first 12 hour diagnosis PE ; 5. sign inform consent . 1 . Previous diagnosis chronic thromboembolic pulmonary hypertension ; 2. active bleeding , clinically relevant bleed previous month diagnosis PE ; 3. peptic ulcer ; 4. major surgery , severe trauma previous month diagnosis PE ; 5. indication chronic anticoagulation ; 6. pregnancy breast feeding ; 7. renal insufficiency ( serum creatinine &gt; 2 mg/dL ) severe hepatic impairment ; 8. hypersensitivity diclofenac , sodium metabisulfite , acetylsalicylic acid ; 9. bronchial asthma ; 10. severe congestive heart failure ; 11. inflammatory bowel disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pulmonary embolism</keyword>
	<keyword>Right ventricular dysfunction</keyword>
	<keyword>Prognosis</keyword>
	<keyword>Inflammation</keyword>
</DOC>